New drug combo aims to save bladders in cancer fight
NCT ID NCT01495676
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tested whether adding gemcitabine to standard cisplatin and radiation therapy could help control muscle-invasive bladder cancer while preserving the bladder. About 69 patients were enrolled to compare the combination against standard treatment. The study was terminated early, so firm conclusions are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- gemcitabine and cisplatin
- What this could lead to
- If successful, this could offer a bladder-sparing treatment option for muscle-invasive bladder cancer, avoiding the need for radical surgery.
- What could go wrong
- This trial was terminated early with only 69 participants, so results are limited. The combination may increase side effects without improving disease control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFILTRATING BLADDER UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CRLC GF Leclerc
Dijon, 21000, France
-
CRLC Val d'Aurelle-Paul Lamarque
Montpellier, 34000, France
-
Centre Alexis Vautrin
Vandœuvre-lès-Nancy, 54511, France
-
Centre Antoine Lacassagne
Nice, 06189, France
-
Centre Francois Baclesse
Caen, 14000, France
-
Centre azuréen de Cancérologie
Mougins, 06250, France
-
Clinique Patseur
Toulouse, 31300, France
-
HEGP
Paris, 75015, France
-
Hopital Henri Mondor
Créteil, 94010, France
-
Hopital saint Louis
Paris, 75010, France
-
Institut Bergonié
Bordeaux, 33000, France
-
Institut de Cancérologie Lucien Neuwirth
Saint-Priest-en-Jarez, 42705, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.